enVVeno Medical Corporation provided an update on enrollment for its ongoing SAVVE (Surgical Anti-reflux Venous Valve Endoprosthesis) U.S. pivotal study for the VenoValve and announced two upcoming investor events. The SAVVE pivotal study is a prospective, non-blinded, single arm, multi-center study of 75 CVI patients. To date, the Company has enrolled 57 patients in the study and expects enrollment to be completed before the end of 2023.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
4.695 USD | -1.16% | -2.07% | -8.17% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-8.17% | 63.32M | |
+58.43% | 59.34B | |
+43.17% | 40.24B | |
-5.13% | 39.88B | |
-5.56% | 28.55B | |
+15.66% | 27.26B | |
-21.30% | 19.23B | |
+33.42% | 12.61B | |
+3.11% | 12.49B | |
+26.61% | 12.28B |
- Stock Market
- Equities
- NVNO Stock
- News enVVeno Medical Corporation
- Envveno Medical Corporation Provides Enrollment Update for Ongoing VenoValve(R) U.S. Pivotal Study